24 . 07 .2025
Press release
Galderma delivers record first half 2025 net sales of 2.448 billion USD and 12.2% year-on-year growth at constant currency, raises full-year top-line guidance
17 . 07 .2025
Press release
Galderma unveils final nine-month data showing lasting efficacy and patient satisfaction with its Injectable Aesthetics portfolio when addressing facial aesthetic changes after medication-driven weight loss
08 . 07 .2025
News story
Scratching the Surface: shedding light on a misunderstood skin disease
25 . 06 .2025
Press release
Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin
18 . 06 .2025
Press release
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years